by Clinical Neuropsychologist | Friday, March 1, 2024 | Dementia
Abstract INTRODUCTION Alzheimer’s disease (AD) is a neurodegenerative disorder with multifactorial etiology, including genetic factors that play a significant role in disease risk and resilience. However, the role of genetic diversity in preclinical AD studies...
by Clinical Neuropsychologist | Friday, March 1, 2024 | Dementia
Abstract Wearable digital technologies capable of measuring everyday behaviors could improve the early detection of dementia-causing diseases. We conducted two systematic reviews following Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA)...
by Clinical Neuropsychologist | Friday, March 1, 2024 | Dementia
Abstract INTRODUCTION Hypertension and diabetes are common cardiovascular risk factors that increase Alzheimer’s disease (AD) risk. However, it is unclear whether AD risk differs in hypertensive individuals with and without diabetes. METHODS Cognitively normal...
by Clinical Neuropsychologist | Thursday, February 29, 2024 | Dementia
Abstract INTRODUCTION Entorhinal cortex (EC) is the first cortical region to exhibit neurodegeneration in Alzheimer’s disease (AD), associated with EC grid cell dysfunction. Given the role of grid cells in path integration (PI)–based spatial behaviors, we...
by Clinical Neuropsychologist | Wednesday, February 28, 2024 | Dementia
Abstract INTRODUCTION Alzheimer’s disease (AD) trial participants are often screened for eligibility by brain amyloid positron emission tomography/cerebrospinal fluid (PET/CSF), which is inefficient as many are not amyloid positive. Use of blood-based biomarkers...
by Clinical Neuropsychologist | Tuesday, February 27, 2024 | Dementia
Abstract INTRODUCTION Alzheimer’s disease (AD) involves the complement cascade, with complement component 3 (C3) playing a key role. However, the relationship between C3 and amyloid beta (Aβ) in blood is limited. METHODS Plasma C3 and Aβ oligomerization tendency...
